Recruitment of 409 anesthesiologists is milestone progress: Maleque
DHAKA, Sept 12, 2021 (BSS) - Health and Family Welfare Minister Zahid Maleque today said recruitment of 409 anesthesiologists in six-grade is a milestone progress considering the COVID-19 situation in the country.
"Anesthesiologist recruitment is very urgent to deal COVID-19 pandemic in remote areas...under the directive of Prime Minister Sheikh Hasina, it has been possible to recruit the large number of anesthesiologists within a short time," he told a function here, an official release said.
The function was held at Osmani Memorial Auditorium in the city on the occasion of the newly recruited junior consultants (Anesthesiology).
The health minister urged the newly recruited anesthesiologists to serve the common people in remote areas with utmost dedication and sincerity.
There is no shortage of vaccines in the country, he said adding," Bangladesh received 54 lakh doses of vaccine at the beginning of the current month and 1.5 crore more coronavirus jabs will arrive in the country within this month.
Bangladesh will get 50 lakh doses of COVID-19 vaccine each week till November, this year, the health minister said.
"We have intensified our efforts to purchase COVID-19 jabs to accelerate the ongoing vaccination campaign to contain the deadly virus," he added.
Maleque said the government has decided to purchase 16.5 core more COVID-19 vaccines from China and WHO facilities. These vaccines are expected to arrive in Bangladesh by January next year, he added.
"Bangladesh will get 2 crore doses of Sinopharm vaccines from China each month...meaning six crore jabs of Sinopharm will arrive in the country within three months," he added.
The Directorate General Health Services (DGHS) sources said as of September 11, Bangladesh collected nearly 40 million vaccine doses, they added
Bangladesh has so far approved eight COVID-19 vaccines to control the deadly disease.
The approved COVID-19 vaccines are from Moderna, Johnson & Johnson, CoronaVac, Pfizer, Covishield, Sputnik V, AstraZeneca and Sinopharm.